Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd offers life science system solutions in China. The company offers cell and gene therapy solutions, including biosafety ferret isolators, sterile pig preparation solutions, aseptic filling workstation, cell preparation workstation, and robotic packaging workstations; drug development and sterile production solutions, comprising sterile packaging, highly activ… Read more
Zhejiang Tailin Bioengineering Co Ltd (300813) - Net Assets
Latest net assets as of September 2025: CN¥790.14 Million CNY
Based on the latest financial reports, Zhejiang Tailin Bioengineering Co Ltd (300813) has net assets worth CN¥790.14 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥934.06 Million) and total liabilities (CN¥143.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥790.14 Million |
| % of Total Assets | 84.59% |
| Annual Growth Rate | 25.94% |
| 5-Year Change | 84.75% |
| 10-Year Change | 742.43% |
| Growth Volatility | 29.9 |
Zhejiang Tailin Bioengineering Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Tailin Bioengineering Co Ltd (2013–2024)
The table below shows the annual net assets of Zhejiang Tailin Bioengineering Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥820.73 Million | +26.22% |
| 2023-12-31 | CN¥650.24 Million | +0.43% |
| 2022-12-31 | CN¥647.45 Million | +30.17% |
| 2021-12-31 | CN¥497.38 Million | +11.96% |
| 2020-12-31 | CN¥444.24 Million | +93.90% |
| 2019-12-31 | CN¥229.11 Million | +17.67% |
| 2018-12-31 | CN¥194.70 Million | +32.91% |
| 2017-12-31 | CN¥146.48 Million | +25.95% |
| 2016-12-31 | CN¥116.31 Million | +19.38% |
| 2015-12-31 | CN¥97.42 Million | +77.02% |
| 2014-12-31 | CN¥55.04 Million | -15.22% |
| 2013-12-31 | CN¥64.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Tailin Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 409.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥250.71 Million | 30.57% |
| Common Stock | CN¥121.20 Million | 14.78% |
| Other Components | CN¥448.14 Million | 54.65% |
| Total Equity | CN¥820.05 Million | 100.00% |
Zhejiang Tailin Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Tailin Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ROX Resources Ltd
AU:RXL
|
$173.38 Million |
|
Kumho Industrial Co Ltd
KO:002995
|
$173.39 Million |
|
REDCENTRIC PLCLS-001
F:6YD
|
$173.52 Million |
|
Norske Skog Asa
OL:NSKOG
|
$173.57 Million |
|
COTGF
OTCQX:COTGF
|
$173.36 Million |
|
Conduent Inc
NASDAQ:CNDT
|
$173.36 Million |
|
Sports Toto Berhad
KLSE:1562
|
$173.30 Million |
|
Torpol S.A.
F:9ZE
|
$173.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Tailin Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 648,762,936 to 820,050,345, a change of 171,287,409 (26.4%).
- Net income of 13,050,671 contributed positively to equity growth.
- Dividend payments of 10,992,566 reduced retained earnings.
- Other comprehensive income decreased equity by 97,318,716.
- Other factors increased equity by 266,548,020.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥13.05 Million | +1.59% |
| Dividends Paid | CN¥10.99 Million | -1.34% |
| Other Comprehensive Income | CN¥-97.32 Million | -11.87% |
| Other Changes | CN¥266.55 Million | +32.5% |
| Total Change | CN¥- | 26.40% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Tailin Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.53x to 3.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥2.85 | CN¥27.17 | x |
| 2014-12-31 | CN¥3.01 | CN¥27.17 | x |
| 2015-12-31 | CN¥1.31 | CN¥27.17 | x |
| 2016-12-31 | CN¥1.77 | CN¥27.17 | x |
| 2017-12-31 | CN¥1.80 | CN¥27.17 | x |
| 2018-12-31 | CN¥2.41 | CN¥27.17 | x |
| 2019-12-31 | CN¥2.12 | CN¥27.17 | x |
| 2020-12-31 | CN¥4.11 | CN¥27.17 | x |
| 2021-12-31 | CN¥4.60 | CN¥27.17 | x |
| 2022-12-31 | CN¥5.75 | CN¥27.17 | x |
| 2023-12-31 | CN¥5.61 | CN¥27.17 | x |
| 2024-12-31 | CN¥7.54 | CN¥27.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Tailin Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.74%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.17x
- Recent ROE (1.59%) is below the historical average (16.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 33.05% | 22.71% | 1.15x | 1.26x | CN¥14.97 Million |
| 2014 | 18.39% | 17.01% | 0.76x | 1.42x | CN¥4.62 Million |
| 2015 | 15.78% | 18.67% | 0.63x | 1.35x | CN¥5.63 Million |
| 2016 | 24.95% | 25.96% | 0.72x | 1.34x | CN¥17.39 Million |
| 2017 | 30.71% | 31.68% | 0.73x | 1.32x | CN¥30.34 Million |
| 2018 | 24.76% | 30.31% | 0.62x | 1.31x | CN¥28.74 Million |
| 2019 | 15.02% | 19.02% | 0.68x | 1.17x | CN¥11.50 Million |
| 2020 | 10.89% | 24.16% | 0.37x | 1.22x | CN¥3.96 Million |
| 2021 | 12.77% | 22.43% | 0.43x | 1.32x | CN¥13.79 Million |
| 2022 | 12.31% | 21.31% | 0.41x | 1.43x | CN¥14.94 Million |
| 2023 | 3.03% | 7.29% | 0.28x | 1.50x | CN¥-45.21 Million |
| 2024 | 1.59% | 3.74% | 0.36x | 1.17x | CN¥-68.95 Million |
Industry Comparison
This section compares Zhejiang Tailin Bioengineering Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Tailin Bioengineering Co Ltd (300813) | CN¥790.14 Million | 33.05% | 0.18x | $173.36 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |